- Home
- AVTX vs MNOV Comparison
AVTX vs MNOV Comparison
Compare AVTX & MNOV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVTX
- MNOV
- Stock Information
- Founded
- AVTX 2011
- MNOV 2000
- Country
- AVTX United States
- MNOV United States
- Employees
- AVTX N/A
- MNOV N/A
- Industry
- AVTX Biotechnology: Pharmaceutical Preparations
- MNOV Biotechnology: Pharmaceutical Preparations
- Sector
- AVTX Health Care
- MNOV Health Care
- Exchange
- AVTX Nasdaq
- MNOV Nasdaq
- Market Cap
- AVTX 90.9M
- MNOV 87.3M
- IPO Year
- AVTX 2015
- MNOV 2005
- Fundamental
- Price
- AVTX $10.13
- MNOV $2.13
- Analyst Decision
- AVTX Buy
- MNOV
- Analyst Count
- AVTX 2
- MNOV 0
- Target Price
- AVTX $35.00
- MNOV N/A
- AVG Volume (30 Days)
- AVTX 59.3K
- MNOV 151.1K
- Earning Date
- AVTX 11-07-2024
- MNOV 11-13-2024
- Dividend Yield
- AVTX N/A
- MNOV N/A
- EPS Growth
- AVTX N/A
- MNOV N/A
- EPS
- AVTX N/A
- MNOV N/A
- Revenue
- AVTX $820,000.00
- MNOV N/A
- Revenue This Year
- AVTX N/A
- MNOV N/A
- Revenue Next Year
- AVTX N/A
- MNOV N/A
- P/E Ratio
- AVTX N/A
- MNOV N/A
- Revenue Growth
- AVTX N/A
- MNOV N/A
- 52 Week Low
- AVTX $3.95
- MNOV $1.12
- 52 Week High
- AVTX $34.46
- MNOV $2.55
- Technical
- Relative Strength Index (RSI)
- AVTX 37.71
- MNOV 62.13
- Support Level
- AVTX $12.00
- MNOV $1.70
- Resistance Level
- AVTX $13.59
- MNOV $2.55
- Average True Range (ATR)
- AVTX 0.96
- MNOV 0.19
- MACD
- AVTX -0.50
- MNOV 0.04
- Stochastic Oscillator
- AVTX 17.42
- MNOV 63.16
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical stage biotechnology company focused on the treatment of immune dysregulation. The company's lead asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).
About MNOV Medicinova Inc
MediciNova Inc is a biopharmaceutical company. The company acquires and develops small-molecule therapeutics for the treatment of diseases with unmet medical needs with a specific focus on the U.S. market. Its products portfolio includes therapeutics such as MN-001, MN-166, MN-221 etc. The firm's current strategy is to focus its development activities on therapeutics for neurological disorders and fibrotic diseases.